Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Milestone for Starpharma's drug delivery program

Starpharma Holdings today released animal data which demonstrated that its dendrimer-docetaxel formulation applying Starpharma’s dendrimer technology to the leading chemotherapy drug docetaxel was significantly more efficacious than docetaxel (Taxotere®) in a breast cancer model.

1 Feb 2012

Lycopene can kill prostate cancer cells

A nutrient in cooked tomatoes has been shown in laboratory studies to slow the growth of or even kill prostate cancer cells.

31 Jan 2012

Size of a man's prostate gland may determine severity of cancer

The size of a man's prostate gland may help predict the severity of cancer, with a smaller prostate being more likely to harbor serious disease.

31 Jan 2012

Fewer getting screened for common cancers: CDC report

According to federal health officials last Thursday, the number of Americans being screened for colon, breast and cervical cancers still fall below national targets.

30 Jan 2012

New research project seeks to understand how prostate cancer becomes resistant to radiotherapy

A new three year research project aimed at improving the effectiveness of radiotherapy treatment for men affected by prostate cancer is taking place at Queen's.

30 Jan 2012

Scientists develop new vaccine to treat cancer at pre-clinical level

Scientists in Trinity College Dublin, Ireland, have developed a new vaccine to treat cancer at the pre-clinical level. The research team led by Professor Kingston Mills, Professor of Experimental Immunology at Trinity College Dublin discovered a new approach for treating the disease based on manipulating the immune response to malignant tumours.

27 Jan 2012

Researchers identify possible cause for loss of tumor suppressor genes

Researchers at Queen's University in Kingston, Canada have identified a possible cause for the loss of a tumour suppressor gene (known as PTEN) that can lead to the development of more aggressive forms of prostate cancer.

27 Jan 2012

CRT launches Acublate to develop HIFU cancer surgery device

Cancer Research Technology, the commercial arm of Cancer Research UK, has today launched Acublate Limited, a spin-out company which will develop a next-generation High Intensity Focused Ultrasound (HIFU) surgery device to treat a range of solid tumour types.

27 Jan 2012

Preoperative MRI may help manage neurovascular bundles during RALP

Preoperative MRI helps surgeons make more informed decisions about nerve-sparing procedures in men with prostate cancer, according to a new study published online in the journal Radiology.

25 Jan 2012

Survey: Percentage of Americans who lack health coverage rose for fourth straight year

The percentage of Americans lacking health insurance coverage rose for the fourth straight year in 2011 to 17.1 percent, a new survey showed Tuesday. The climb has been steady since Gallup began tracking whether adults have health insurance in 2008. Four years ago, only 14.8 percent of adults lacked health insurance.

25 Jan 2012

Urological cancer experts to examine latest treatment, research findings at 27th Annual EAU Congress

International urological cancer experts will examine the latest treatment and research findings at the 27th Annual EAU Congress in Paris, France on 24-28 February 2012.

25 Jan 2012

GUMC licenses worldwide rights of 'theranostic' to BioMetrx

Georgetown University Medical Center (GUMC) has licensed worldwide rights of a potential novel cancer therapy and diagnostic, or "theranostic," to BioMetrx, LLC. The agent was invented by two Georgetown researchers.

25 Jan 2012

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

Dutaseride may help prevent progression of early stage prostate cancer: Study

A new study suggests that men with early stage prostate cancer may benefit with drugs that can slow or stop the cancer’s progress. Less than 10 percent of the 100,000 men each year who are diagnosed with early-stage prostate cancer and have the option of leaving the cancer in place. Rest get it removed using surgery or radiation. But those treatments can have serious side effects like impotence and incontinence.

24 Jan 2012

InSightec seeks FDA premarket approval for ExAblate treatment of pain palliation of bone metastases

InSightec Ltd, the leader in MR guided Focused Ultrasound therapy, announced that it has submitted a premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for its ExAblate treatment of pain palliation of bone metastases.

24 Jan 2012

KSU professor turns to nutrition to tackle prostate cancer

A Kansas State University professor is turning to nutrition to tackle prostate cancer. Brian Lindshield, assistant professor of human nutrition, is helping men make more informed diet decisions by studying foods and dietary supplements that may reduce the risk of prostate cancer. Prostate cancer is one of the most common forms of cancer among men in the United States.

24 Jan 2012

New book explores how patients and doctors deal with cancer

Jonathan Waxman, a professor of oncology, was inspired to write a book by his conversations with his patients. Here, he gained insight into his patients' fears, hopes, and the impact the disease has on their lives. In The Elephant in the Room, Waxman explores the relationship of patient and specialist, how both sides deal with cancer, their interactions, and what doctors actually mean when talking to their patients.

24 Jan 2012

OPKO acquires two new prostate cancer biomarkers from Arctic Partners

OPKO Health, Inc. today announced the acquisition of an exclusive license from Arctic Partners Ab Oy for two biomarkers in the kallikrein family which, used together with prostate specific antigen (PSA), can reduce the need for prostate biopsies by over 50%.

24 Jan 2012

Dutasteride delays prostate cancer progression in men

For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a three-year international clinical trial led by Dr. Neil Fleshner, Head of the Division of Urology, University Health Network.

24 Jan 2012

NCI-funded project aims to shed new light on implications for bone metastasis in prostate cancer

Prostate cancer is the most frequent and second deadliest cancer men face. A team of Wayne State University researchers recently received $363,660 from the National Cancer Institute of the National Institutes of Health for the project - "Bone-induced c-kit in prostate cancer cells: implications for bone metastasis" - that aims to shed new light on implications for bone metastasis in prostate cancer.

21 Jan 2012